This trial is evaluating whether Nivolumab will improve 2 primary outcomes, 7 secondary outcomes, and 2 other outcomes in patients with Hodgkin Disease. Measurement will happen over the course of 1 year after primary outcome is met.
This trial requires 78 total participants across 2 different treatment groups
This trial involves 2 different treatments. Nivolumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Signs of HD may include an enlarged, swollen cervical lymph node. Symptoms may be painless or painful and involve the groin or thighs. Signs of HD typically persist for 3 months or more. HD involves the bone marrow, and causes high levels of white cells.\n" - Anonymous Online Contributor
"The cure rate is between 10-20%. Early detection and treatment is essential. Treatment is necessary to prevent irreversible deformities, but the main goal of treatment is, most importantly, to control the disease." - Anonymous Online Contributor
"When an erythematous mass is of unknown cause, the following differential diagnoses should arise in the differential diagnosis and should be considered: pyoderma gangrenosum (early), bacterial cellulitis (late), and lymphoma (malignant cells)." - Anonymous Online Contributor
"The incidence of hodgkin disease is rising in the United States. Despite the declining incidence of Hodgkin disease in the United Kingdom, the prevalence of the disease in the United Kingdom is increasing. A study of the incidence of hodgkin disease among the UK population is warranted." - Anonymous Online Contributor
"This preliminary analysis suggests that many patients with Hodgkin's live well with chemotherapy. More research is needed as to the most effective chemotherapy and the long-term effects of treatment, such as the risk of developing second primary cancer and treatment-related side effects such as bone marrow failure, which may lead to secondary death." - Anonymous Online Contributor
"In children, Hodgkin's disease is a type of highly aggressive (and often fatal) non-Hodgkin lymphoma characterized by the malignancy of B cells affecting the spleen and lymph nodes.\n" - Anonymous Online Contributor
"There are many nivolumab development programs underway and many new immunotherapies are in progress. It’s very exciting for immunotherapy as research is shifting out of the traditional target molecules (e.g. CTLA4 T cell checkpoint inhibitors) and into target tissues and organs and the immune microenvironment." - Anonymous Online Contributor
"We have found an increased risk of Hodgkin disease amongst children with Down syndrome who had an autoimmune etiology in the absence of Epstein Barr virus (EBV) infection." - Anonymous Online Contributor
"Nivolumab seems to be used more frequently in combination with other treatment types. Furthermore, in patients treated with nivolumab and chemotherapy a significant improvement in OS, PFS, and CFS was evident." - Anonymous Online Contributor
"Common side effects in this pooled analysis of 2101 patients included: fatigue, insomnia, nausea and/or vomiting, constipation, diarrhea, injection-site reactions, and stomatitis. Less common side effects included upper respiratory tract infections (7/1076 (6.4%)), peripheral edema (1/1076 (0.9%)), bronchospasm (1/1076 (0.9%)), hypertension (1/1076 (0.9%)), and hypothyroidism (1/1076 (0.9%)). Nivolumab monotherapy was associated with an increased rate of infections and infusion-related reactions compared with chemotherapy alone in patients with Hodgkin's lymphoma." - Anonymous Online Contributor
"The average survival rate for patients with good risk stage III-IHD is 98%; 94% in stage III-IIHL. Survival rate for stage IIHL (70% 5 yr; 72% 10 yr) and IVHL (55% 5 yr; 46% 10 yr) are lower in comparison to these two risk groups." - Anonymous Online Contributor